TY - JOUR
T1 - Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan
AU - Senoo, Satoru
AU - Ninomiya, Kiichiro
AU - Hotta, Katsuyuki
AU - Kiura, Katsuyuki
N1 - Funding Information:
Conflict of interest Satoru Senoo has no conflicts of interest. Kiichiro Ninomiya received honoraria from Astrazeneca, MSD, Bristol-Myers Squibb, and Ono pharmaceutical. Katsuyuki Hotta received honoraria from Astrazeneca, and MSD, and research funding from Chugai pharmaceutical, Eli Lilly Japan, Bristol-Myers Squibb, and Astellas Pharma. Katsuyuki Kiura received honoraria from Astrazeneca, and Eli Lilly Japan, and research funding from Astrazeneca, and Chugai pharmaceutical.
Publisher Copyright:
© 2019, Japan Society of Clinical Oncology.
PY - 2019/5/15
Y1 - 2019/5/15
N2 - Squamous cell carcinoma of the lung is associated with smoking in its development and comprises about 20–30% of all lung cancers. Its treatment strategy had been limited for the past decades, inevitably resulting in the poor outcome. However in the 2010s, it has dramatically changed mainly with the recent clinical introduction of immune checkpoint inhibitors. In this review, we will introduce various clinical studies involving squamous cell carcinoma of the lung.
AB - Squamous cell carcinoma of the lung is associated with smoking in its development and comprises about 20–30% of all lung cancers. Its treatment strategy had been limited for the past decades, inevitably resulting in the poor outcome. However in the 2010s, it has dramatically changed mainly with the recent clinical introduction of immune checkpoint inhibitors. In this review, we will introduce various clinical studies involving squamous cell carcinoma of the lung.
KW - Cytotoxic drug
KW - Immune checkpoint inhibitor
KW - Squamous cell carcinoma of the lung
UR - http://www.scopus.com/inward/record.url?scp=85062685719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062685719&partnerID=8YFLogxK
U2 - 10.1007/s10147-019-01424-y
DO - 10.1007/s10147-019-01424-y
M3 - Review article
C2 - 30847617
AN - SCOPUS:85062685719
VL - 24
SP - 461
EP - 467
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
SN - 1341-9625
IS - 5
ER -
